Progenics Pharmaceuticals (PGNX) Q2 results: Revenues: $10M (+156.4%); Azedra sales: $0.3M; Royalty income: $3.6M (+2.9%); License and other revenue: $6.1M.
Net Loss: ($19.7M) (-29.6%); loss/share: ($0.23) (-15.0%); Quick Assets: $84.8M (-38.4%).
The Company completed enrollment ahead of schedule in Phase 3 CONDOR trial of PyLTM (18F-DCFPyL); topline data expected by end of 2019.
Previously: Progenics Pharmaceuticals EPS misses by $0.04, beats on revenue (Aug. 9)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.